CA
NZ
UK
AU
IND
US
In the third-line pivotal PiNACLE trial, 44 evaluable patients showed a 91% overall response rate and a 77% complete response rate, with median progression-free survival not yet reached. In a second-line Phase 1/2 cohort of 37 evaluable patients, the response rate was 95% and …
MedlineBrandsales rose 7% to $3.6 billion, andSupplyChain Solutions rose 14% to $4.2 billion. Adjusted EBITDA reached $960 million, including an $81 million benefit fromTariffrefunds. Supply Chain SolutionsMarginwas 4.4%, held back by lower-margin prime vendor mix and higher operating costs.
Nearly nine in ten patients experienced a clinical benefit at six months, according to the company, and the FDA approved a US labeling update for the Symplicity renal denervation system.
The stock has risen several hundred percent this year, so any new catalyst is landing on a very different base than it did twelve months ago.
Bernstein named Molina, Centene and Elevance as the most direct insurer beneficiaries, citing possible delays to Medicaid cuts and restored enhanced ACA subsidies.
Adjusted EBITDA was $1.9 million, against a loss of $4.7 million, and the net loss narrowed to $1.7 million, or $0.02 per share.
Adjusted sales grew 4% to DKK 79.2 billion, with US operations up 1% and International Operations up 8%. Adjusted operating profit rose 27%, and free cash flow exceeded DKK 28 billion. Obesity sales grew 22%, and the company now treats 5.6 million obesity patients, …
Nurix said it no longer expects milestones or royalties on that asset, which removes roughly $455 million in potential payments.
Ocugen signed an exclusive OCU400 license for the Middle East and North Africa with Roots Pharmaceutical, worth up to $4 million in upfront and early milestones, up to $255 million in sales milestones and a royalty. It is the second regional OCU400 license after …
The company reported a third-quarter net loss of $53.1 million, or $1.10 per share, against $35.5 million a year earlier.
Please wait processing your request...